Amlan International Announces Two Technical Support Key Hires for Animal Health and Nutrition Business


CHICAGO, IL--(Marketwire - August 14, 2008) - Amlan International announces the hiring of Fang Chi, Ph.D. and Jonathan Broomhead, Ph.D., to focus on worldwide technical support and new product development.

"I am very excited to have Dr. Chi and Dr. Broomhead join the team," said Ron Cravens, Vice President of Amlan International. "They both bring a wealth of knowledge and skill to our group that allows us to provide the technical support and guidance needed to become a major contributor in the livestock health and nutrition markets."

Dr. Fang Chi, Technical Services Director for Amlan International will, provide scientific leadership to sales and marketing in support of existing and new products. Chi received his doctorate from Ohio State University in nutrition and animal science. He has published many papers on myriad aspects of animal health and nutrition and managed animal health technical services throughout Asia and the United States.

Dr. Jonathan Broomhead, Chief Research Scientist for Amlan International will, manage all laboratory and field research for new product development. Broomhead received his doctorate from the University of Missouri in animal science specializing in monogastric nutrition. He has extensive experience developing and managing research trials and laboratory assays particularly for poultry.

Dr. Chi and Dr. Broomhead join Jeff Turner, Regional Sales & Marketing Manager for Asia, Margarita Santa, Regional Sales Manager for Latin America and Glen Gabriel, Regional Sales Manager for the United States.

About Amlan International

Amlan International is the animal health and nutrition division of Oil-Dri Corporation of America. Amlan International develops and markets products used in the global livestock health and nutrition markets. Additional information can be found on the division's website, www.amlan.com.

Certain statements in this press release may contain forward-looking statements that are based on our current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs, and our management's assumptions. In addition, we, or others on our behalf, may make forward-looking statements in other press releases or written statements, or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, and conference calls. Words such as "expect," "outlook," "forecast," "would," "could," "should," "project," "intend," "plan," "continue," "believe," "seek," "estimate," "anticipate," "believe," "may," "assume," variations of such words and similar expressions are intended to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Such statements are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially including, but not limited to, the dependence of our future growth and financial performance on successful new product introductions, intense competition in our markets, volatility of our quarterly results, risks associated with acquisitions, our dependence on a limited number of customers for a large portion of our net sales and other risks, uncertainties and assumptions that are described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and other reports we file with the Securities and Exchange Commission. Should one or more of these or other risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results may vary materially from those anticipated, intended, expected, believed, estimated, projected or planned. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except to the extent required by law, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this press release, whether as a result of new information, future events, changes in assumptions, or otherwise.

Contact Information: Contact: Ronda J. Williams Phone 312 321 1887 Fax 312 321 9525 www.amlan.com